Rchr
J-GLOBAL ID：200901087186140750
Update date: Jul. 24, 2024
MIURA Katsuhiro
ミウラ カツヒロ | MIURA Katsuhiro
Affiliation and department：
Job title：
Associate Professor
Research field (1)：
Hematology and oncology
Research theme for competitive and other funds (1)：
- 2022 - 2025 Novel biomarker search of TAFRO syndrome and multicentric Castleman disease
Papers (74)：
-
Noriyoshi Iriyama, Katsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, Kazuhide Iizuka, Takashi Hamada, Takashi Koike, Kazuya Kurihara, Toshihide Endo, Tomohiro Nakayama, et al. Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience. Leukemia & lymphoma. 2023. 64. 1. 171-177
-
Shuhei Matsumoto, Hiromichi Takahashi, Takashi Hamada, Katsuhiro Miura, Masaru Nakagwa, Kazuya Kurihara, Toshihide Endo, Takashi Koike, Kazuhide Iizuka, Noriyoshi Iriyama, et al. [Thrombotic microangiopathy with gastrointestinal hemorrhage during carfilzomib therapy for multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2023. 64. 4. 255-259
-
Takashi Hamada, Hiromichi Takahashi, Masaru Nakagawa, Hironao Nukariya, Shun Ito, Toshihide Endo, Kazuya Kurihara, Takashi Koike, Kazuhide Iizuka, Shimon Ohtake, et al. Pulmonary Veno-Occlusive Disease after Autologous Stem Cell Transplantation. Case reports in oncology. 2023. 16. 1. 338-346
-
Hiromichi Takahashi, Katsuhiro Miura, Masaru Nakagawa, Haruna Nishimaki, Shun Ito, Hironao Nukariya, Kazuya Kurihara, Toshihide Endo, Takashi Koike, Takashi Hamada, et al. Pirarubicin-based intensive chemotherapy followed by consolidative high-dose chemotherapies for peripheral T-cell lymphomas: A noncomparative phase 2 study. Hematological oncology. 2022. 40. 5. 1094-1096
-
Katsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, Takashi Hamada, Yoshihito Uchino, Kazuhide Iizuka, Shimon Ohtake, Noriyoshi Iriyama, Yoshihiro Hatta, Hideki Nakamura. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma. Expert review of anticancer therapy. 2022. 22. 6. 583-595
ｍore...
MISC (16)：
-
前田 嘉信, 近藤 英生, 山本 和彦, 増成 太郎, 三浦 勝浩, 瀧澤 淳, 正木 康史, 村上 純, 富田 直人, 神野 正敏. 再発性/難治性DLBCL患者におけるifosfamide、etoposide、dexamethasone、中程度用量cytarabineを併用したrituximab(R-IDEA)療法に関する第II相研究(A phase II study of rituximab plus ifosfamide, etoposide, dexamethasone and intermediate dose cytarabine(R-IDEA) in patients with relapsed/refractory DL. 日本リンパ網内系学会会誌. 2018. 58. 115-115
-
Hiromichi Takahashi, Sumiko Kobayashi, Katsuhiro Miura, Daisuke Kurita, Yoshihiro Hatta, Masahiko Sugitani, Shimon Otake, Masaru Nakagawa, Masashi Sakagami, Yoshihito Uchino, et al. Clinical Significance of Co-Expression of MYC and BCL2 Protein in Advanced Diffuse Large B-Cell Lymphoma Treated with a Dose-Intensified Immunochemotherapy. BLOOD. 2015. 126. 23
-
Katsuhiro Miura, Jun Konishi, Takaaki Miyake, Makita Masanori, Atsuko Hojo, Yasufumi Masaki, Masatoshi Uno, Jun Ozaki, Chikamasa Yoshida, Daigo Niiya, et al. A New Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. BLOOD. 2015. 126. 23
-
Akihiro Uchiike, Tatsuya Hayama, Katsuhiro Miura, Daisuke Tsutsumi, Masatoshi Hayasaka, Yoshihiro Hatta, Masami Takei, Yoshikazu Yoshida. A clinical prediction model for infusion reaction to rituximab. ANNALS OF ONCOLOGY. 2015. 26. 80-80
-
Katsuhiro Miura, Satomi Kiso, Masaru Nakagawa, Hiromichi Takahashi, Yoshito Uchino, Hitomi Kodaira, Noriyoshi Iriyama, Masashi Sakagami, Shimon Ohtake, Sumiko Kobayashi, et al. Clinical Significance of Arbekacin Sulfate for High-Risk Infections Among Patients with Hematological Malignancies. BLOOD. 2014. 124. 21
ｍore...
Lectures and oral presentations (10)：
-
Consolidation therapy using 90Y-ibritumomab tiuxetan after bendamustine and rituximab in patients with relapsed follicular lymphoma; a multicenter, phase II study (BRiZ2012)
(The 24th European Hematology Association congress 2019)
-
CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012)
(The 24th Congress of the European Hematology Association 2019)
-
Bendamustine and rituximab (BR) followed by 90Y-ibritumomab tiuxetan (90Y-IT) for relapsed follicular lymphoma; a preliminary analysis of a multicenter, prospective phase II study (BRiZ 2012)
(European Society of Medical Oncology 2018 congress 2018)
-
Bendamustine and rituximab (BR) followed by 90Y-ibritumomab tiuxetan (90Y-IT) for relapsed follicular lymphoma; , a preliminary analysis of a multicenter, prospective phase II study (BRiZ 2012)
(The ESMO 2018 Congress 2018)
-
A New Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP
(57th annual meeting of the American Society of Hematology 2015)
ｍore...
Professional career (1)：
Return to Previous Page
